Therapeutic Solutions International Successfully Treats Veteran Navy SEAL Suffering from Chronic Traumatic Encephalopathy with JadiCell™ Adult Stem Cells Under Right to Try Law

Rhea-AI Summary

Therapeutic Solutions International (TSOI) announced successful treatment of a Navy SEAL Veteran suffering from Chronic Traumatic Encephalopathy (CTE) using JadiCell adult stem cells. The treatment involved two injections with no adverse events reported. The company is committed to clinical trials, having received Phase III clearance for COVID-19 ARDS and planning a Phase I/II trial for CTE. The initiative provides pro bono access to military personnel. The CEO expressed pride in supporting veterans amid rising suicide rates, emphasizing the urgent need for new therapeutic strategies.

Positive

• Successful treatment of a Navy SEAL Veteran with JadiCell stem cells.
• No adverse events reported from the treatment.
• Initiatives to provide treatments pro bono to military personnel.
• Phase III clearance received for COVID-19 ARDS trials.
• Plans to launch Phase I/II trial for CTE.

Negative

• None.

ELK CITY, Idaho, Sept. 13, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today successful treatment of a United States Navy SEAL Veteran suffering from Chronic Traumatic Encephalopathy (CTE). The patient received 2 injections of the JadiCell adult stem cells, no treatment associated adverse events were noted.  

The cells were provided under a newly initiated program under which Therapeutic Solutions International provides access to its technologies Pro Bono, to members of the Armed Forces who have defended the United States.

"We are 100% committed to performing proper clinical trials, as seen by the recent Phase III clearance to utilize these cells in patients with COVID-19 ARDS. We are also working with the FDA to launch our Phase I/II trial in CTE," said Dr. James Veltmeyer, Chief Medical Officer of the Company. "With a suicide rate of 20 veterans per day, it is imperative that we vigorously explore novel therapeutic strategies in patients for which other approaches have failed or don't exist. Given the excellent safety profile of these cells, and promising preclinical data, in our opinion it would be criminal not to provide access to these cells under very specific circumstances."

CTE is caused by repeated injuries to the brain causing chronic inflammation, deterioration of neuronal communication, and death of brain cells. These culminate in various symptomologies including depression, violence, and suicidality.

"My father was a combat veteran Marine of WWII and Korea; I fully understand the extreme sacrifices made by members of our Armed Forces in the defense of our Freedom, our Nation, and our National Security," said Timothy Dixon, President and CEO of the Company. "We are a Company that is proud of being in a position to give something back to the bravest segment of our society."

About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/ 

ir@tsoimail.com

View original content:https://www.prnewswire.com/news-releases/therapeutic-solutions-international-successfully-treats-veteran-navy-seal-suffering-from-chronic-traumatic-encephalopathy-with-jadicell-adult-stem-cells-under-right-to-try-law-301375088.html

SOURCE Therapeutic Solutions International

FAQ

What recent treatment did Therapeutic Solutions International (TSOI) conduct for a Navy SEAL Veteran?

Therapeutic Solutions International successfully treated a Navy SEAL Veteran suffering from Chronic Traumatic Encephalopathy (CTE) using JadiCell adult stem cells.

What are JadiCell adult stem cells used for in the recent TSOI treatment?

JadiCell adult stem cells were used to treat Chronic Traumatic Encephalopathy (CTE) in a Navy SEAL Veteran.

What commitment has TSOI made regarding clinical trials?

TSOI has committed to performing proper clinical trials, including a Phase I/II trial for CTE and has received Phase III clearance for COVID-19 ARDS.

Are there any reported adverse events related to the TSOI treatment?

No treatment-associated adverse events were noted during the JadiCell treatment.

What initiative does TSOI have for members of the Armed Forces?

TSOI provides access to its technologies pro bono for members of the Armed Forces.